Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SOFTSWISS Releases Free Sportsbook Budget Calculator

SOFTSWISS, a global iGaming software provider, publishes a free Sportsbook Budget Calculator . The comprehensive tool will help businesses considering launching a sports betting project to calculate the costs and benefits.Incorporating years of experience from the SOFTSWISS Sportsbook team, the Sportsbook Budget Calculator touches on all vital points in creating a sports betting business plan. With the insights on local market peculiarities provided by

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS13 May 2024 at 16:20NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: BINGAB Barents Investment Group ABPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive OfficerIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 62626/4/6 ____________________________________________Transaction date: 2024-05-10

Lytix Biopharma AS - New share capital registered

Oslo, Norway, 13 May 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or the "Company") on 25 April 2024 and 26 April 2024 regarding the issuance of a total of 9,541,984 shares (the "Offer Shares") by the Company's extraordinary general meeting and the board of directors pursuant to a board authorization relating to a partially guaranteed share offering (the "Offering"). The share capital increases relating to the Offering have today been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is

The patient study on Zeqmelit® is fully recruited

All 50 patients in AcuCort's phase IV study ZEQ001 for Zeqmelit® have been enrolled.The phase IV study ZEQ001 on the oral film Zeqmelit®, an innovative oral film for the treatment of severe and acute allergies, commenced at the end of January. Now, 50 patients have been allocated the oral film for use when needed for acute allergic reactions. "The patient recruitment has exceeded our already high expectations, indicating the significant patient need for our pharmaceutical product," says Jonas Jönmark, CEO of AcuCort. "Furthermore, the study results can be used in an application to be

SOFTSWISS Expands to Bulgaria: European Growth Through Partnership

SOFTSWISS, a leading iGaming software provider , entered the Bulgarian market through a partnership with operator Topwin.bg. This strategic move strengthens and expands the SOFTSWISS brand in Europe.SOFTSWISS has secured certification from Gaming Laboratories International (GLI) for use in the Bulgarian market, ensuring all technical and legal requirements are met. The partner utilises the SOFTSWISS Casino Platform, the Sportsbook, the SOFTSWISS Game Aggregator, and Affilka, all fully prepared and technically

Kojamo plc: Managers' Transactions

Kojamo plc Stock Exchange Release, 13 May 2024 at 4:06 p.m. EESTKojamo plc: Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Annica Ånäs Position: Member of the Board/Deputy member Issuer: Kojamo plc LEI: 7437007YPUOQZ8OV1R42 Notification type: INITIAL NOTIFICATION Reference number: 62527/6/6 ____________________________________________ Transaction date: 2024-05-10 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000312251 Nature of transaction: RECEIPT OF A

Kojamo plc: Managers' Transactions

Kojamo plc Stock Exchange Release, 13 May 2023 at 4:05 p.m. EESTKojamo plc: Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Andreas Segal Position: Member of the Board/Deputy member Issuer: Kojamo plc LEI: 7437007YPUOQZ8OV1R42 Notification type: INITIAL NOTIFICATION Reference number: 62518/7/6 ____________________________________________ Transaction date: 2024-05-10 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000312251 Nature of transaction: RECEIPT OF A

Kojamo plc: Managers' Transactions

Kojamo plc Stock Exchange Release, 13 May 2024 at 4:04 p.m. EESTKojamo plc: Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Mikko Mursula Position: Member of the Board/Deputy member Issuer: Kojamo plc LEI: 7437007YPUOQZ8OV1R42 Notification type: INITIAL NOTIFICATION Reference number: 62500/7/6 ____________________________________________ Transaction date: 2024-05-10 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000312251 Nature of transaction: RECEIPT OF A

Kojamo plc: Managers' Transactions

Kojamo plc Stock Exchange Release, 13 May 2024 at 4:03 p.m. EESTKojamo plc: Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Veronica Lindholm Position: Member of the Board/Deputy member Issuer: Kojamo plc LEI: 7437007YPUOQZ8OV1R42 Notification type: INITIAL NOTIFICATION Reference number: 62499/8/8 ____________________________________________ Transaction date: 2024-05-10 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000312251 Nature of transaction: RECEIPT OF

Kojamo plc: Managers' Transactions

Kojamo plc Stock Exchange Release, 13 May 2024 at 4:02 p.m. EESTKojamo plc: Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Anne Koutonen Position: Member of the Board/Deputy member Issuer: Kojamo plc LEI: 7437007YPUOQZ8OV1R42 Notification type: INITIAL NOTIFICATION Reference number: 62497/6/6 ____________________________________________ Transaction date: 2024-05-10 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000312251 Nature of transaction: RECEIPT OF A

Kojamo plc: Managers' Transactions

Kojamo plc Stock Exchange Release, 13 May 2024 at 4:01 p.m. EESTKojamo plc: Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Kari Kauniskangas Position: Member of the Board/Deputy member Issuer: Kojamo plc LEI: 7437007YPUOQZ8OV1R42 Notification type: INITIAL NOTIFICATION Reference number: 62496/9/8 ____________________________________________ Transaction date: 2024-05-10 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000312251 Nature of transaction: RECEIPT OF

Kojamo plc: Managers' Transactions

Kojamo plc Stock Exchange Release, 13 May 2024 at 4:00 p.m. EESTKojamo plc: Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Mikael Aro Position: Member of the Board/Deputy member Issuer: Kojamo plc LEI: 7437007YPUOQZ8OV1R42 Notification type: INITIAL NOTIFICATION Reference number: 62494/7/6 ____________________________________________ Transaction date: 2024-05-10 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000312251 Nature of transaction: RECEIPT OF A

SciBase announces outcome in the directed issue of units

On 5 April 2024 SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, subject to subsequent approval by the general meeting, on directed issues of a total of 77,891,769 units consisting of shares and warrants of series TO 2, with deviation from the shareholders preferential rights, to a total approximate amount of SEK 33 million (the "Directed Issue"). The subscription price in the Directed Issue amounted to SEK 0.42 per unit, corresponding to SEK 0.42 per share. The extraordinary general meeting on 13 May 2024 resolved to approve the

BlueNord: The Nomination Committee's Proposal to the Annual General Meeting

Oslo, 13 May 2024: Reference is made to the stock exchange notice published by BlueNord ASA ("BlueNord" or the "Company") on 12 April 2024 regarding the Annual General Meeting in BlueNord to be held on 14 May 2024. The nomination committee has today submitted its recommendation to the annual general meeting, which is found attached here and will also be made available on the Company's website www.bluenord.com. This information is subject to disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.   *** Contact:Cathrine Torgersen, Chief

SRV Group Plc: Managers' Transactions – Ari Lehtoranta

SRV GROUP PLC    MANAGERS’ TRANSACTIONS    13 MAY 2024   AT 15:30 EESTSRV Group Plc: Managers' Transactions – Ari Lehtoranta  Notification under the EU Market Abuse Regulation, article 19 SRV Group Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Ari Lehtoranta Position: Member of the Board/Deputy member  Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 62533/5/4 ____________________________________________

SRV Group Plc: Managers' Transactions – Hannu Leinonen

SRV GROUP PLC    MANAGERS’ TRANSACTIONS    13 MAY 2024   AT 15:30 EESTSRV Group Plc: Managers' Transactions – Hannu Leinonen  Notification under the EU Market Abuse Regulation, article 19 SRV Group Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Hannu Leinonen Position: Member of the Board/Deputy member  Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 62538/5/4 ____________________________________________

SRV Group Plc: Managers' Transactions – Heli Iisakka

SRV GROUP PLC    MANAGERS’ TRANSACTIONS    13 MAY 2024   AT 15:30 EESTSRV Group Plc: Managers' Transactions – Heli Iisakka  Notification under the EU Market Abuse Regulation, article 19 SRV Group Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Heli Iisakka Position: Member of the Board/Deputy member  Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 62536/5/4 ____________________________________________ Transaction

SRV Group Plc: Managers' Transactions – Matti Ahokas

SRV GROUP PLC    MANAGERS’ TRANSACTIONS    13 MAY 2024   AT 15:30 EESTSRV Group Plc: Managers' Transactions – Matti Ahokas  Notification under the EU Market Abuse Regulation, article 19 SRV Group Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Matti Ahokas Position: Member of the Board/Deputy member  Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 62545/5/4 ____________________________________________ Transaction

SRV Group Plc: Managers' Transactions – Tuomas Kokkila

SRV GROUP PLC    MANAGERS’ TRANSACTIONS    13 MAY 2024   AT 15:30 EESTSRV Group Plc: Managers' Transactions – Tuomas Kokkila  Notification under the EU Market Abuse Regulation, article 19 SRV Group Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Tuomas Kokkila Position: Member of the Board/Deputy member Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 62542/4/4 ____________________________________________ Transaction

#24-47 Information regarding the last day of trading in paid subscribed shares in Hoi Publishing AB

The rights issue in Hoi Publishing AB is now registered with the Swedish Companies Registration Office and the last day of trading in paid subscribed shares has been set for May 16, 2024.    Information regarding the affected instrument:   Listing name: Hoi Publishing BTB Exchange symbol: HOI BTB ISIN-code: SE0021630134 CFI-code: ESNUFR FISN-code: HOIPUBLISH/SH B Last day of trading: 2024-05-16 Instrument-ID: EECV Market-ID: NSME Segment-ID: NSSE   For more information about this Market Notice, please contact us by e-mail, marketsurveillance@ngm.se

Aqilion expands its pipeline

AQILION AB (publ) announces an expansion of its pipeline through the nomination of PKCtheta as the target of a new immunology project.Aqilion’s aims at the discovery and development of differentiated and effective treatments for autoimmune and inflammatory diseases. The PKCtheta kinase plays a critical role in T-cell receptor signaling and is believed to be centrally involved in the pathogenesis of T-cell mediated inflammatory and autoimmune diseases e.g. ulcerative colitis and rheumatoid arthritis. PKCtheta has garnered significant attention from the pharmaceutical industry and, using our

Stena Line reinforces its Irish Sea management to drive growth in the region

Swedish ferry operator Stena Line has announced strategic changes to its management team aimed at further enhancing its position as a market leader and driving continued growth in the region.Over recent years, Stena Line's Irish Sea operation has experienced significant expansion solidifying its status as a cornerstone of the company's network. With 13 ships operating across 7 routes and providing a market leading 240 sailings each week, the Irish Sea has become an increasingly vital component of Stena Line's business. The recent launch of the Dublin – Liverpool freight route further

Trill Impact Ventures co-leads USD 25 million series B financing round in May Health

Advancing novel treatment for women suffering from Polycystic Ovary Syndrome related infertility.Trill Impact Ventures, announces that it together with Bpifrance, has co-led a USD 25m series B financing round in May Health, a French-American medical device company targeting Polycystic Ovary Syndrome (PCOS) related infertility. The round also saw participation from existing May Health investor Sofinnova Partners. Proceeds will advance the clinical development of May Health’s innovative device, as well as reaching CE marking that will enable market introduction in select European countries.

There are no items matching the current filter
There are no more items matching the current filter
Back to top